# Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial

*PRI Rank #10 · Topics and Trends in Most Cited Antibiotic Resistance in Bacteria Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/antibiotic-resistance-in-bacteria/2026/rank-10*

| Field | Value |
| --- | --- |
| Rank | #10 |
| 18m citations | 86 |
| Journal | The Lancet Infectious Diseases |
| Year | 2024 |
| DOI | 10.1016/s1473-3099(24)00499-7 |
| Corresponding authors | José Miguel Cisneros |
| Institution | Tel Aviv Sourasky Medical Center, Israel |

**Ranking page:** [Topics and Trends in Most Cited Antibiotic Resistance in Bacteria Papers, Class of 2026](https://pri.pepkio.com/top-papers/antibiotic-resistance-in-bacteria/2026)

**Paper link:** [10.1016/s1473-3099(24)00499-7](https://doi.org/10.1016/s1473-3099(24)00499-7)

## Topics

aztreonam-avibactam · meropenem · Gram-negative bacteria · Severe infections · REVISIT trial · phase 3 trial · open-label trial · multinational study · randomised trial · comparative effectiveness · Antimicrobial resistance · β-lactamase inhibitor · carbapenem comparator · combination therapy

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Antibiotic Resistance in Bacteria Papers, Class of 2026. https://pri.pepkio.com/top-papers/antibiotic-resistance-in-bacteria/2026. Accessed 2026-07-17.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```